Poseida Therapeutics Stock (NASDAQ:PSTX)
Previous Close
$9.45
52W Range
$1.87 - $9.58
50D Avg
$5.12
200D Avg
$3.48
Market Cap
$923.97M
Avg Vol (3M)
$1.23M
Beta
0.54
Div Yield
-
PSTX Company Profile
Poseida Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing therapeutics for patients with high unmet medical needs. The company develops P-PSMA-101, an autologous chimeric antigen receptor T cell (CAR-T) product candidate that is in Phase I trial for the treatment of patients with metastatic castrate resistant prostate cancer (mCRPC). It is also developing P-BCMA-ALLO1, which is in Phase I trial to treat patients with relapsed/refractory multiple myeloma; and P-MUC1C-ALLO1 that is in Phase I trial for treating a range of solid tumors, including breast, ovarian, and other epithelial-derived cancers. In addition, the company engages in the development of P-CD19CD20-ALLO1 for B cell malignancies and other autoimmune diseases; and P-BCMACD19-ALLO1, an allogeneic, off-the-shelf CAR-T product candidate in preclinical development for multiple myeloma. Further, it is developing P-PSMA-ALLO1, an allogeneic CAR-T product candidate for treating mCRPC. Additionally, the company engages in the development of P-OTC-101 and P-FVIII-101 that are clinical stage liver-directed gene therapies; and other allogeneic dual CAR candidates. It has a research collaboration and license agreement with Takeda Pharmaceutical Company Limited. The company was incorporated in 2014 and is headquartered in San Diego, California.
PSTX Performance
Peer Comparison
Ticker | Company |
---|---|
CUE | Cue Biopharma, Inc. |
RVMD | Revolution Medicines, Inc. |
RVPH | Reviva Pharmaceuticals Holdings, Inc. |
STOK | Stoke Therapeutics, Inc. |
IPSC | Century Therapeutics, Inc. |
GBIO | Generation Bio Co. |
PLRX | Pliant Therapeutics, Inc. |
DYN | Dyne Therapeutics, Inc. |
ANTX | AN2 Therapeutics, Inc. |
MLYS | Mineralys Therapeutics, Inc. |
LTRN | Lantern Pharma Inc. |
INAB | IN8bio, Inc. |
PEPG | PepGen Inc. |
PASG | Passage Bio, Inc. |
PHVS | Pharvaris N.V. |
MOLN | Molecular Partners AG |
CYTK | Cytokinetics, Incorporated |